MELISSA KRISHT: Open Payments
NPI 1316467616 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$327 in 8 payments from 7 companies in 2025. Trend: 2023 $269 · 2024 $95 · 2025 $327
Food & beverage: $327
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $97 |
| Vanda Pharmaceuticals Inc. | 1 | $91 |
| ABBVIE INC. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
Products named: COBENFY, FANAPT, VRAYLAR, CAPLYTA, REXULTI, TRINTELLIX, INGREZZA.
Industry payments across AR — which companies pay providers there.
